PTC Therapeutics, Inc.
votoplam
Huntington's disease
Resolved
70days ago
Phase 2 readout · Apr 28, 2026
What's at stake
Phase 2 trial results for votoplam in Huntington's disease are due Apr 28, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“On April 28, 2026, PTC Therapeutics, Inc. (the “Company”) reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study of votoplam.”